Drugs / MVA CS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01450280 | Dec 2011 → Oct 2012 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00121771 | Jan → Jul 2004 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT01739036 Comparator | Jan → Oct 2013 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT01623557 Comparator | Apr → Nov 2012 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA CS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00121771 ↗ |
| Modality | Vaccine | “the chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) replication-deficient viral vectored vaccines encoding the circumsporozoite protein (CS) of P. falciparum.” PMID 25522180 ↗ Dec 2014 |
| Route | Intramuscular | “Some of the volunteers will receive a booster vaccination with MVA CS administered via intramuscular route.” NCT01450280 ↗ |